Experience

Pinteon Therapeutics

• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Jun 2017 - Present

  Scientific leader for small team developing therapeutic antibodies for neurologic disease. Completely virtual scientific, translational and clinical development effort that extends from cell free experiments to development of a GMP-compatible production cell line and anticipated clinical entry. Primary responsibility for overseeing generation of in vitro and in vivo pharmacology data sets for IND submission, development and validation of translational biomarkers, clinical biomarker implantation and execution and clinical study design. Also played a significant role in preparing Pinteon for broader exposure in the scientific and partnering community



Ani Consulting, LLC

• Business Consulting and Services

• President

  • Jun 2017 - Present

  Consulting with for-profit and not-for-profit enterprises regarding target identification, pre-clinical and clinical therapeutic development for neurologic diseases including ALS, AD, PD and neurodevelopmental, monogenetic diseases. Helping non-profits to make funding decisions as well as providing strategic input for areas of development. Advising commercial entities on leveraging proprietary technology for potential targets for neurologic, neuromuscular and neurodevelopmental disease. Consulting with for-profit and not-for-profit enterprises regarding target identification, pre-clinical and clinical therapeutic development for neurologic diseases including ALS, AD, PD and neurodevelopmental, monogenetic diseases. Helping non-profits to make funding decisions as well as providing strategic input for areas of development. Advising commercial entities on leveraging proprietary technology for potential targets for neurologic, neuromuscular and neurodevelopmental disease.



FORMA Therapeutics, Inc.

• Head of Neuroscience

  • Jun 2017 - Jun 2019

  Built a neuroscience team that leveraged the oncology-focused FORMA technology platform for neurological applications. The team operated in a nearly virtual manner leveraging CROs and academic collaborations to drive discovery programs to clinical candidates. Lead asset disease was out-licensed and corporate strategic decision taken to terminate neuroscience efforts in June 2019. Built a neuroscience team that leveraged the oncology-focused FORMA technology platform for neurological applications. The team operated in a nearly virtual manner leveraging CROs and academic collaborations to drive discovery programs to clinical candidates. Lead asset disease was out-licensed and corporate strategic decision taken to terminate neuroscience efforts in June 2019.



Bristol-Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director, Genetically Defined Disease Biology and Head, Clinical Biomarkers, GDD

  • Mar 2010 - May 2017

  In my role of Director of Biology, GDD, I have led scientific Discovery teams to produce clinical candidates for including large and small molecule therapeutics for neurologic and muscle wasting diseases. In addition, I have driven these Discovery teams to generate data sets and endpoints that have been directly translated to clinical studies. As Head of Clinical Biomarkers in GDD, I have implemented the assays in the clinic and written sections of clinical protocols and regulatory documents. My role spans the preclinical to clinical space as I maintain direct supervision of PhD scientists in Discovery and work within a matrixed team in development to implement translational endpoints in Development.



EnVivo Pharmaceuticals

• United States
• Hospitals and Health Care

• Vice Preseident, Research

  • Apr 2006 - Dec 2009

  Responsible for devising and implementing research strategy for the company. Delivered 2 preclinical candidates in less than 4 years with team of approximately 20 internal scientists. Contributed to preclinical and clinical development of lead program. Attracted significant external, non-dilutive funding. Responsible for devising and implementing research strategy for the company. Delivered 2 preclinical candidates in less than 4 years with team of approximately 20 internal scientists. Contributed to preclinical and clinical development of lead program. Attracted significant external, non-dilutive funding.



Pfizer

• Events Services
• 1 - 100 Employee

• Executive Director

  • May 1991 - Mar 2006

  Responsible for an increasing scope of activities over a 15 year career in CNS Discovery at the Pfizer Groton site including leading project teams to deliver preclinincal candidates, leading early clinical management to guide NCEs through development, participating in licensing due diligence and finally in an operations role that explored alternative research processes and paradigms. Member of senior CNS Discovery and Biology leadership teams. Responsible for an increasing scope of activities over a 15 year career in CNS Discovery at the Pfizer Groton site including leading project teams to deliver preclinincal candidates, leading early clinical management to guide NCEs through development, participating in licensing due diligence and finally in an operations role that explored alternative research processes and paradigms. Member of senior CNS Discovery and Biology leadership teams.